Bibliographic information
GuidelineWHO Guidelines for malaria, 14 March 2023
Year of Publication2023
Issuing InstitutionWHO
Recommendation
Maintained
Short-course standard dose primaquine treatment: To prevent relapse, an additional treatment option of using primaquine 0.5 mg/kg/day for seven days is recommended to treat P. vivax or P. ovale malaria in children and adults (except pregnant women, infants aged < 6 months, women breastfeeding infants aged < 6 months, women breastfeeding older infants unless they are known not to be G6PD deficient, and people with G6PD deficiency).
Recommended in favor
Strong
Certainty of evidence
Very low
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO guidelines for malaria, 25 November 2022.
Year2022
InstitutionWorld Health Organization